Lv11
40 积分 2025-08-07 加入
Correction: Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
1小时前
已完结
[Long-term response to second-line treatment with sacituzumab govitecan in a patient affected by brain disease and early relpased TNBC.]
10天前
已关闭
Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates
12天前
已完结
Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody–drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer
12天前
已完结
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
13天前
已完结
Knockdown of ENO1 promotes autophagy dependent‐ferroptosis and suppresses glycolysis in breast cancer cells via the regulation of CST1
18天前
已完结
Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody–drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer
19天前
已完结
Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates
19天前
已完结
Understanding the chemistry & pharmacology of antibody–drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives
20天前
已完结
[TNBC, stage IV: a patient's journey, from standard options to the new era of ADC.]
20天前
已完结
皖公网安备34019202002308
